Abstract: The present invention relates to TNF-? binding molecules and nucleic acid sequences encoding TNF-? binding molecules. In particular, the present invention relates to TNF-? binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-? and that are capable of neutralizing TNF-? at low concentrations. Preferably, the TNF-? binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for thereaputic purpose are also provided.

Abstract: The present invention relates to TNF-? binding molecules and nucleic acid sequences encoding TNF-? binding molecules. In particular, the present invention relates to TNF-? binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-? and that are capable of neutralizing TNF-? at low concentrations. Preferably, the TNF-? binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

Abstract: The present invention relates to TNF-? binding molecules and nucleic acid sequences encoding TNF-? binding molecules. In particular, the present invention relates to TNF-? binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-? and that are capable of neutralizing TNF-? at low concentrations. Preferably, the TNF-? binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

Abstract: aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Conjugates comprising aPL analogs and nonimmunogenic valency platform molecules are provides as are novel nonimmunogenic valency platform molecules and linkers. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.

Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

Abstract: The present invention provides domain 1 ?2GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 ?2GPI polypeptides and mimetics. Domain 1 of ?2GPI has been shown to bind to anti-cardiolipin (?2GPI-dependent antiphospholipid) antibodies, which are associated with several pathologies, such as thrombosis and fetal loss. The domain 1 ?2GPI polypeptides may be used to detect ?2GPI-dependent antiphospholipid antibodies in a sample. The invention further provides methods of inducing tolerance using these domain 1 ?2GPI polypeptides.

Abstract: The present invention provides optimized heteromeric variable region binding fragments and antibodies comprising optimized heteromeric variable region binding fragments. Preferably, the optimized heteromeric variable region binding fragments exhibit optimized activity compared to donor heteromeric variable regions and have unvaried human frameworks. The present invention also provides methods of making the optimized heteromeric variable region binding fragments.

Abstract: The present invention relates to TNF-&agr; binding molecules and nucleic acid sequences encoding TNF-&agr; binding molecules. In particular, the present invention relates to TNF-&agr; binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-&agr; and that are capable of neutralizing TNF-&agr; at low concentrations. Preferably, the TNF-&agr; binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

Abstract: The present invention relates to TNF-&agr; binding molecules and nucleic acid sequences encoding TNF-&agr; binding molecules. In particular, the present invention relates to TNF-&agr; binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-&agr; and that are capable of neutralizing TNF-&agr; at low concentrations. Preferably, the TNF-&agr; binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).

Abstract: A CW radar range measuring system having a transmitter adapted to transmit a continuous wave radar signal phase encoded in accordance with a code and a receiver adapted to receive a radar return from the transmitted radar signal. The receiver includes an analog to digital converter section for converting a sequence of samples of the radar return into a corresponding sequence of digital words. A digital correlator/integrator is fed by the digital words and the code for providing an indication of radar return energy as a function of range from the transmitter. A processor is fed by the digital correlator/integrator for determining, from the indicated energy, target range. The system includes a frequency spectrum analyzer for determining a frequency spectrum of the digital words and wherein the processor determines the target Doppler frequency from such determined frequency spectrum.

Abstract: A radar system having a transmitter for transmitting a series of radio frequency (RF) pulses with sequential, incrementally changing carrier frequencies. A receiver receives energy from multiple scattering points of an object reflecting such transmitted RF pulses. The received energy from each one of such scattering points includes a series of radio frequency (RF) pulses corresponding to the transmitted pulses delayed in time, .tau., from the transmitted pulses an amount proportional to the range to such scattering point and shifted in frequency from the carrier frequency an amount proportional to the velocity of such scattering point. The receiver includes a heterodyning section, responsive to a range tracking error signal, .epsilon..sub.R, and a velocity tracking error signal, .DELTA..sub.VEL, for producing a series of pulsed signals for each one of the scattering points. Each one of the pulsed signals for any given scatterer sequentially changes in phase, .phi., at a rate, .DELTA..phi./.DELTA.